Page 162 - Drug Class Review
P. 162
Page 111 of 205
Drug Effectiveness Review Project
Author and Year: Reisberg et al., 2003; 59 Rive et al., 2004; 76 Doody et al., 2004 77
To assess the efficacy of MEM in outpatients with moderate to severe AD
placebo N/A 28 weeks 126 Probable AD according to DSM-IV and NINCDS/ARDA criteria; baseline MMSE scores of 3 - 14; stage of 5 or 6 on the GDS; stage of 6a or greater on the Functional Assessment Staging Instrument; reliable VaD; clinically significant neurological or medical diseases; clinically significant co-existing medical Antidepressive treatment and chloral hydrate allowed; anticonvulsant, antiparkinson, hypnotic,
Drugs Merz Pharmaceuticals; NIH Setting: Multi-center (32) memantine 20 mg/d 28 weeks 126 caregivers; CT or MRI of the brain within previous 12 months anxiolytic, and neuroleptic agents not allowed
Alzheimer Country: US Study design: RCT Sample size: 252 conditions
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
